Exobiosphere
Luxembourg · Biotech · Space tech
Exobiosphere runs automated experiments in microgravity to help pharmaceutical and biotechnology researchers study disease and test drug candidates.
Drug discovery in orbit
Researchers use microgravity to observe biological changes that are difficult to reproduce in conventional laboratory conditions. Exobiosphere combines that environment with its Orbital High-Throughput System, automating many experiments within a space mission.
Its services cover identifying molecular targets, testing drug responses and characterising disease traits. The company describes a platform capacity of more than 2,000 experiments per mission, serving pharmaceutical companies, biotechnology developers and research institutions.
From disease models to drug testing
The work connects disease models developed in microgravity with screening experiments intended to help researchers select promising drug candidates. Oncology, ageing, neurodegeneration and cardiovascular biology are among the therapeutic areas described by the company.
- Product
- Orbital High-Throughput System
- Customers
- Pharma, biotech and research institutions
- Luxembourg office
- Esch-sur-Alzette
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Jeune Entreprise Innovante grant | €1M | Luxembourg Ministry of the Economy — Participant |